Notice2023-12504
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 12, 2023
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 112 (Monday, June 12, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 112 (Monday, June 12, 2023)]
[Notices]
[Pages 38096-38097]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-12504]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Medical CBRN Defense Consortium
Notice is hereby given that, on April 6, 2023, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense Consortium
(``MCDC'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing changes in
its membership. The notifications were filed for the purpose of
extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under
[[Page 38097]]
specified circumstances. Specifically, Decryptor, Inc., Richardson, TX;
Joint Research & Development, Inc., Stafford, VA; Northstar Emergency
Management LLC, Pittsburgh, PA; Redwire Space Components LLC,
Marlborough, MA; SaponiQx, Inc., Lexington, MA; UniVox Technical
Solutions LLC dba UniVox LLC, Tijeras, NM; Vega Technology Group LLC,
North Canton, OH; and Zalgen Labs LLC, Frederick, MD have been added as
parties to this venture.
Also, Allegheny-Singer Research Institute dba AHN Institute,
Pittsburgh, PA; BioCryst Phamaceuticals, Inc., Durham, NC; Encryptor,
Inc., Richardson, TX; Healion Bio, Inc., Ijamsville, MD; ImmPORT
Therapeutics, Inc. dba Antigen Discovery, Inc., Irvine, CA; Kuprion,
Inc., San Jose, CA; MBio Diagnostics, Inc. dba LightDeck Diagnostics,
Boulder, CO; Medicago USA, Inc., Durham, NC; Merck, Sharpe and Dohme
Corp., Whitehouse Stations, NJ; and Tutela Pharmaceuticals, Inc.,
Vernon Hills, IL have withdrawn as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and MCDC intends to file additional
written notifications disclosing all changes in membership.
On November 13, 2015, MCDC filed its original notification pursuant
to section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to section 6(b) of the Act on
January 6, 2016 (81 FR 513).
The last notification was filed with the Department on January 4,
2023. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on January 25, 2023 (88 FR 4850).
Suzanne Morris,
Deputy Director, Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2023-12504 Filed 6-9-23; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on June 12, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.